Join
Live feed
·
PRReleasevia Quantisnow
Psyence Biomedical Ltd. logo

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

ByQuantisnow·Wall Street's wire, on your screen.
PBM· Psyence Biomedical Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PBM (Psyence Biomedical Ltd.) and more on Quantisnow.

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care | Quantisnow